Chemomab Therapeutics Ltd.
CMMB Nasdaq
SEC CIK 1534248
Follow Chemomab Therapeutics Ltd.
Weekly email: filings, results
EPS, diluted
$0.02
−53.8% vs prior year
Operating cash flow
−$11.1M
+27.7% vs prior year
Operating income
−$112M
−8.7% vs prior year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$11.1M |
| FY24 | −$15.4M |
| FY23 | −$23.6M |
| FY22 | −$20.4M |
| FY21 | −$12.6M |
| FY20 | −$5.3M |
| FY19 | −$16.6M |
| FY18 | −$14.4M |
| FY17 | - |